Follow us on Twitter
twitter icon@FreshPatents


Infectious patents

      

This page is updated frequently with new Infectious-related patent applications.

SALE: 260+ Infectious-related patent PDFs



Diazabicyclooctane compounds
Or a stereoisomer, tautomer or pharmaceutically acceptable salt or ester thereof, wherein a, r1 and r2 are defined herein. Also described are pharmaceutically acceptable compositions of formula (ii) compounds as well as methods for utilizing the compounds of formula (ii) and the pharmaceutically acceptable compositions of formula (ii) compounds as antibacterial agents and β-lactamase inhibitors, useful in the treatment of infectious diseases..

Vaccine compositions and methods of use thereof
Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, sirna, rna or dna to papcs or mhc class ii positive cells (e.g. Tumor cells).
University Of Miami


Treatment of infectious diseases
Disclosed herein are methods for treating or preventing a disease comprising administering a pharmaceutical composition comprising a therapeutically-effective amount of nitazoxanide to a subject having the disease, wherein the disease is causally linked to infection by one or more pathogens selected from the group consisting of members of the genus ebolavirus, members of the genus marburgvirus, members of the species dengue virus, human immunodeficiency viruses 1 and 2, and members of the species mycobacterium tuberculosis.. .
Children's Medical Center Corporation


Antibodies directed against interleukin 36 receptor (il-36r)
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (il-36r). The invention provides an il-36r-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.


Engineered opsonin for pathogen detection and treatment
The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (mbl), which is an abundant natural serum protein that is part of the innate immune system.
President And Fellows Of Harvard College


Targeted apheresis using binding agents or ligands immobilized on membranes
This invention teaches a method of targeted apheresis that can be used to treat a variety of different diseases including infectious diseases, autoimmune disorders, and reducing circulating biomarkers associated with certain disorders e.g. Pre-eclampsia.

Oral delivery system
The present invention provides a delivery system for the treatment and/or prevention of infectious pathological changes, including compositions comprising polyhexanide, various pharmaceutical formulations, and processes for using these formulations in oral treatment modalities.. .

Anti-cd27 antibodies
The present invention relates to anti-cd27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.. .
Merck Sharp & Dohme B.v.


Antibody molecules to lag-3 and uses thereof
Antibody molecules that specifically bind to lag-3 are disclosed. The anti-lag-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders..
Immutep S.a.


Immunomodulators
The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company


Ebna1 inhibitors and their use

Pharmaceutical compositions of the invention comprise ebna1 inhibitors useful for the treatment of diseases caused by ebna1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise ebna1 inhibitors useful for the treatment of diseases caused by latent epstein-barr virus (ebv) infection.
The Wistar Institute Of Anatomy And Biology

Anti-human vista antibodies and use thereof

The invention provides antagonistic and agonistic anti-human vista antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block vista's suppressive effects on t cell immunity and thereby promote t cell immunity.
Janssen Pharmaceuticals, Inc.

Substituted urea depsipeptide analogs as activators of the clpp endopeptidase

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators with the clpp endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of search in the particular art and is not intended to be limiting of the present invention..
St. Jude Children's Research Hospital

Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof

The present invention relates to a novel compound of 4′-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same and an application thereof. Specifically, the present invention relates to a phosphamide derivative of 4′-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same, a use thereof in the preparation of a medicine for preventing or treating abnormal cell proliferation diseases (for example, tumors or cancers and related diseases) or virus infectious diseases, and a method of using the same for preventing or treating abnormal cell proliferation diseases (for example, tumors or cancers and related diseases) or virus infectious diseases..
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

Bacterial topoisomerase i inhibitors with antibacterial activity

The present invention provides compounds as bacterial topoisomerase inhibitors with antibacterial activity. The present invention also provides pharmaceutical compositions comprising at least one of the compounds and methods of using the compounds and pharmaceutical compositions as antibacterial agents for treating infectious diseases..
University Of Hawaii

Method for treating infectious diseases using emissive energy

The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation.
Marv Enterprises, Llc

Pd-1 peptide inhibitors

This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (pd-1). These peptides block the interaction of pd-1 with its ligand pd-l1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis..
Leidos, Inc.

Ibv strains and uses thereof

The present invention relates to novel infectious bronchitis virus strains and the uses thereof. The invention particularly relates to an inactivated or attenuated ibv, as well as to vaccine compositions comprising the same and the uses thereof to vaccinate avians.
Biomune Company

Anti-tigit antibodies

The present invention relates to anti-tigit antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.. .
Merck Sharp & Dohme Corp.

Macrolides with modified desosamine sugars and uses thereof

Provided herein are macrolide compounds of formula (i) and (i-n) for the treatment of infectious diseases and inflammatory conditions. The 14-membered ketolides and 14-, 15-, and 16-membered azaketolides described herein comprise modified sugars which are desosamine or mycaminose analogs.
President And Fellows Of Harvard College

Immune checkpoint inhibitors, compositions and methods thereof

For formula (i) compounds r1, r2, x1, y1 and n are as defined in the specification. The inventive formula (i) compounds are inhibitors of the pd-1/pd-l1 protein/protein binding or functional interaction and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer and infectious diseases..

Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom

The present invention is directed to novel nucleotide and amino acid sequences of porcine epidemic diarrhea virus (“pedv”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine pedv genotypes and isolates.
Zoetis Services Llc

Composition for treatment or prevention of infectious inflammatory diseases, or composition for immune enhancement, comprising tryptophanyl-trna synthetase as an active ingredient

The composition of the present invention can be effectively used for preventing or treating diseases of humans and animals caused by infection from bacteria, viruses or fungi and the like by inhibiting infections such as bacterial, viral, and fungal infections at an early stage particularly through activating innate immune response.. .

Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles

A method is provided in various embodiments for determining a profile data set for a subject with infectious disease or inflammatory conditions related to infectious disease based on a sample from the subject, wherein the sample provides a source of rnas. The method includes using amplification for measuring the amount of rna corresponding to at least 2 constituents from table 1.
Life Technologies Corporation

Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes

Disclosed are capsid-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated raav vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian vascular system, and complications from type i diabetes.
University Of Florida Research Foundation, Inc.

Mzb1, a novel b cell factor, and uses thereof

The marginal zone (mz) and b1 subsets of b cells, which differ from conventional follicular (fo) b cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in mz and b1 b cells but at low level, if at all, in fo b cells.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.

Compounds useful as immunomodulators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use.
Bristol-myers Squibb Company

Methods and coupling an electromagnetic radiation conduction system into a catheter

Methods and apparatus for the inactivation of infectious agents in, on or around a catheter residing in a patient's body cavity. The method comprises a coupling adapter for facilitating the transmission of non-ultraviolet sterilizing electromagnetic radiation (emr) substantially axially along an optical element into the catheter body.

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein

The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g.
Curevac Ag

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Landos Biopharma, Inc.

Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

A diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of procalcitonin (pct) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic, as well as a kit for performing the method and methods of treatment based thereon.. .
B.r.a.h.m.s Gmbh

Antibodies directed against programmed death-1 (pd-1)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (pd-1) protein. The invention provides a pd-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Bcr-complex-specific antibodies and methods of using same

This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Leukocyte esterase detection from throat swab

The present invention relates to the field of infectious diseases. The invention specifically relates to the diagnostic test for acute bacterial pharyngitis.

Method and system for tissue treatment with critical/supercritical carbon dioxide

Methods of decontaminating bone tissue and an apparatus or system for the same are provided. The methods can be multi-batch processes and include contacting the bone tissue having contaminants with carbon dioxide to decontaminate the bone tissue and to form carbon dioxide having contaminants.
Warsaw Orthopedic, Inc.

Immunomodulatory fusion proteins and uses thereof

The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a t cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease..
Fred Hutchinson Cancer Research Center

System and inactivation of infectious pancreatic necrosis virus (ipnv) using medium pressure ultraviolet (uv) light

A method and a system is provided for inactivation of infectious pancreatic necrosis virus (ipnv) comprising illuminating a liquid containing ipnv with a lamp emitting a continuous broad band of ultraviolet (uv) light. The uv lamp may be “tuned” to optimize ipnv inactivation.
Atlantium Technologies Ltd

Methods and apparatus to inactivate infectious agents on a drainage catheter residing in a body cavity

Methods and apparatus for the inactivation of infectious agents in, on or around a catheter residing in a patient's body cavity. The method comprises a coupling adapter for facilitating the transmission of non-ultraviolet sterilizing electromagnetic radiation (emr) substantially axially along an optical element into the catheter body.

Vacuum assisted skin penetrating appliance with external interface

A system and method for a modular external interface for a skin penetrating appliance is provided. The modular device prevents internalization of bacteria, other infectious agents, or other unwanted materials from entering the access point for a catheter, steinman pin, kirschner wires, or other percutaneous instruments.
Viaderm, Llc

Glucocerebroside treatment of disease

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or t cell receptor ligand, preferably a glucosylceramide, to a mammalian subject.
Enzo Therapeutics, Inc.

Glucocerebroside treatment of liver disorders

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or t cell receptor ligand, preferably a glucosylceramide, to a mammalian subject.
Enzo Therapeutics, Inc.

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur

Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing

Methods are provided for predicting a subject's infection status using high-throughput t cell receptor sequencing to match the subject's tcr repertoire to a known set of disease-associated t cell receptor sequences. The methods of the present invention may be used to predict the status of several infectious agents in a single sample from a subject.
Fred Hutchinson Cancer Research Center

Capsid-modified raav vectors and methods of use

Disclosed are tyrosine-modified raav vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant raav vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of raav vectors..
University Of Florida Research Foundation, Incorporated

Molecular antigen array

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array.
Kuros Biosciences Ag

Anti-pd-1 antibodies

The present invention relates to anti-pd-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have cdrs as provided in the enclosed sequences.
Aduro Biotech Holdings, Europe B.v.

Icos binding proteins

The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Centre National De La Recherche Scientifique (cnrs)

Immunotherapeutic vaccine and antibody combination therapy

The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s)..
Transgene Sa

Methods for preventing or treating infectious diseases caused by extracellular microorganisms, including antimicrobial-resistant strains thereof, using gallium compounds

The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant staphylococcus aureus (mrsa), vancomycin-resistant enterococcus faecalis (vre), e.
Cahn School Of Medicine At Mount Sinai

Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies

The present invention relates generally to a medicinal solution, and more particularly to a medicinal solution which is to be continuously or pulse-delivered for the purpose of treating various ocular diseases, conditions, or maladies, such as keratoconus, infectious keratitis, severe inflammatory conditions, and ocular surface neoplasia. In particular, the medicinal solution comprises the combination of a medication for treating one of the aforenoted or similar diseases, conditions, or maladies, and an anesthetic for rendering the patient comfortable during the treatment procedure..

Polymer-based antimicrobial compositions and methods of use thereof

Provided is a polymer-based antimicrobial composition that is non-toxic, water soluble, and that mitigates the transmission of infectious diseases from surfaces. The composition comprises a cationic polymer, at least one adhesion promoter, optionally organic and/or inorganic particles that are photocatalytically active in visible light, and a carrier, in which the components of the composition are not covalently bound to one another.
Exion Labs Inc.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

Hepatitis c virus replication at extrahepatic sites has been suggested; however, complete viral replication has only been confirmed in hepatocytes. Here we show that human adipogenic dlk-1+ stem cells (hadsc) freshly isolated from hcv-infected individuals contained viral transcripts, replication intermediates and viral antigens in vivo, and viral transcripts increased in supernatants upon prolonged ex vivo culture.
Frontier Bio-drug Development Limited

Method for preparing antigen-specific cytotoxic t-cells by using activated b-cells and use thereof

Disclosed in the present application are: a method for preparing in vitro/ex vivo antigen-specific cytotoxic t-cells by using b cells treated with biological response modifier; and a use thereof. The cytotoxic t-cells prepared by the method of the present application can be used advantageously for treating infectious disease and cancer and the like..
Seoul National University R&db Foundation

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Targeted conjugates encapsulated in particles and formulations thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided.
Tarveda Therapeutics, Inc.

Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells

Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.. .
Anthrogenesis Corporation

Novel multivalent nanoparticle-based vaccines

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus.
The Usa, As Represented By The Secretary Department Of Health And Human Services

Information spread in social networks through scheduling seeding methods

A method for information spread in one or more social networks, the method may include receiving or generating social network information that represents members of the one or more social networks and links between the members; repeating, for each point in time out of multiple points in time, the steps of: determining, in response to budget constraints and current statuses of the members, and the current influence vectors of the members social circle, at least one target member that is non-infected during the point of time and should be infected before the next point in time, to provide an increase in the final number of infected members; wherein the statuses of the members comprises (i) infected and infectious, (ii) non-infected and (iii) infected and non-infectious; and sending, at a cost, the information to the at least one target member, before the next point in time.. .
Ramot At Tel-aviv University Ltd.

Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Disclosed herein are il-4 cytokine compositions with enhanced biological activity having increased selectivity for il-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (il-4) muteins.
The Board Of Trustees Of The Leland Stanford Junior University

Methods for making arrays for high throughput proteomics

Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapid production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for their immunological activity with regard to an infectious agent..
The Regents Of The University Of California

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)

The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.

Enclosure for containment of material

An enclosure for containment and removal of hazardous material from objects is described, having a frame comprising a plurality of bars and a plurality of joints, each joint being releasably connectable to at least two bars, a flexible bag attachable to the frame, the bag being at least in part transparent, and comprising a resealable seam, and at least one adjusting device for tightening or loosening the bag on the frame. Usually, the enclosure, in use, is a negative pressure enclosure.
Claverend Innovations Limited

Methods and apparatus to deliver therapeutic, non-ultraviolet electromagnetic radiation to inactivate infectious agents and/or to enhance healthy cell growth via a catheter residing in a body cavity

Methods and apparatus provide therapeutic electromagnetic radiation (emr) for inactivating infectious agents in, on or around a catheter residing in a patient's body cavity and/or for enhancing healthy cell growth. The method comprises transmitting non-ultraviolet therapeutic emr substantially axially along an optical element in a lumen of the catheter body and/or the catheter body.

Synthetic nanoparticles for delivery of immunomodulatory compounds

The present disclosure provides a synthetic nanoparticle comprising a peptide nucleic acid (pna) oligomer conjugated to a lipid, wherein the pna oligomer noncovalently complexes with an immunomodulatory compound, thereby forming a nanoparticle. The nanoparticles are useful to elicit immune responses and can be used to treat a broad range of cancers and infectious diseases..
Massachusetts Institute Of Technology

Tryptophan is a pro-drug for infectious diseases and cancers

The innovation provides compositions and methods for treating infectious diseases and cancers, wherein said, in vitro, in higher active tdo (tryptophan 2,3-dioxygenase) sick cells that include cancer and infectious cells, tryptophan is capable of transferring into kynurenine derives to induce cells apoptosis; in vivo, tryptophan will turn into indican. Indican is capable of competing phosphorylation in the subject, competitively inhibiting process to form gtp, atp, dgtp, datp, that are essential for dna/rna synthesis; inhibiting host or invading gene amplification, or interfere with plk(polo like kinase) phosphorylation to trigger cell apoptosis.

Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fcgammarinhibiting

The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant fc region, wherein said variant fc region comprises at least one amino acid modification relative to a wild-type fc region, which variant fc region binds an fcγr that activates a cellular effector (“fcγractivating,” such as fcγriia or fcγriiia) and an fcγr that inhibits a cellular effector (“fcγrinhibiting,” such as fcγriia) with an altered ratio of affinities relative to the respective binding affinities of such fcγr for the fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by fcγr is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by fcγr is desired (e.g., inflammation, autoimmune disease)..
Macrogenics, Inc.

Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells

The invention describes a method and compounds for the prevention of immune responses towards allofactors, towards viral vectors used for gene therapy and gene vaccination, towards proteins to which subjects are naturally exposed, towards genetically-modified organisms and towards undesirable effects related to vaccine administration for allergic or infectious diseases.. .
Imnate Sarl

Enterococcus faecalis and/or enterococcus faecium antigen

The present invention generally relates to the field of detecting and preventing infectious diseases caused by enterococcus faecalis and/or enterococcus faecium. More specifically, the invention relates to an enterococcus faecalis and/or enterococcus faecium antigen which comprises at least one unit having the following general formula:.
Universitätsklinikum Freiburg

Inhibitors of trka kinase

The present invention is directed to the compounds of formula i which are inhibitors of tropomyosin-related kinase a (trka): formula (i) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, ra, rb, rc, rd, r1, r2, l and het-ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (ngf) receptor trka such as pain, inflammation or an inflammatory diseases, cancer, atherosclerosis, restenosis, thrombosis, neurodegenerative diseases, erectile dysfunction (ed), skin disorders, autoimmune disease like multiple sclerosis, sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination..
Gvk Biosciences Private Limited

Compounds, compositions and associated methods comprising 3-aryl quinolines

Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed..
The United States Government As Represented By The Department Of Veterans Affairs

Sanitizing apparatus support

The present disclosure presents sanitization devices and methods. More particularly, the disclosure presents devices and methods that significantly reduce or eliminate the activity of germs, bacteria and/or other infectious microorganisms from a variety of objects.
Sanitizall Corp.

Adaptation of attenuated infectious bronchitis virus (ibv) to embryonic kidney cells and vaccine thereby produced

Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (ibv). The methods typically include passing a heterogeneous attenuated population of ibv in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of ibv in embryonated chicken eggs (ece) in order to obtain passaged attenuated population of ibv.
Auburn University

Rna virus attenuation by alteration of mutational robustness and sequence space

The application generally relates to the attenuation of a rna virus or of a clone thereof and involves the alteration of sequence space, more particularly the reduction, of mutational robustness of said rna virus or clone. The means of the application are more particularly dedicated to the attenuation of an infectious rna virus or clone, for the production of immunogenic composition or vaccine.
Institut Pasteur

Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent

A lactic acid bacterium-containing composition including a lactic acid bacterium having a human papillomavirus (hpv) e7 protein-derived polypeptide on a surface thereof, wherein the hpv e7 protein-derived polypeptide is included in an amount of 0.03 μg to 1.0 μg per 1×108 lactic acid bacteria; a therapeutic oral pharmaceutical composition for at least one of an hpv infectious disease and an hpv-associated tumor which includes the lactic acid bacterium-containing composition; and a mucosal immunity-inducing agent which includes the lactic acid bacterium-containing composition.. .
Japan Health Sciences Foundation

Use of prostacyclin antagonists for treating ocular surface nociception

The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort..
Jenivision Inc.

Non-streaking durable composition for cleaning and disinfecting hard surfaces

The present invention relates to quaternary ammonium disinfecting cleaning compositions comprising a quaternary ammonium compound, an alkyl a polyglycoside with a cmc greater than 1000 ppm and a chelant. Beneficially, the compositions provide residual sanitizing efficacy without diminished performance and without scale formation when diluted with hard water.
Ecolab Usa Inc.

Cyclic dinucleotides useful for the treatment of inter alia cancer

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Oxathiazole thiazolium hsp 70 inhibitors

Provided herein are compounds of formula (i) which are, inter alia, useful allosteric inhibitors of hsp70. The compounds and methods provided are useful for the treatment of cancer, infectious and neurodegenerative diseases..
The Regents Of The University Of California

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution.
Tarveda Therapeutics, Inc.

Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases.
Riken

Stable formulations for the oral administration of amphotericin b and related methods

The present invention provides oral ampb and/or protease inhibitor formulations and their use to treat infectious disease, including hiv.. .
Ico Therapeutics Inc.

Therapeutic agent for keratoconjunctive disorders

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a rarγ agonist as an active ingredient is provided.
Yamaguchi University

Methods for immunomodulation of cancer and infectious disease therapy

The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (trip) compound with an effective amount of the therapeutic agent. In particular embodiments, the trip compound enhances the immune response of the subject to the therapeutic agent.
The Regents Of The University Of California

Method for identifying pathogens of bacterial infectious diseases by using bacteria-derived nanovesicles

The present invention relates to a method for predicting causative factors (bacteria) of serious bacterial infectious diseases in a clinical sample containing bacteria-derived nano-sized extracellular vesicles, that is, nanovesicles, through the analysis of the genes contained in the nanovesicles. According to the present invention, information on bacteria of serious bacterial infection can be provided, a causative factor of the bacterial infection can be predicted, and the resistance of the bacteria to antibiotics can be predicted..
Md Healthcare Inc.

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.. .
Duke University

Novel compound and antiviral agent containing same as active ingredient

An object of the invention is to provide a compound that can be utilized as an antiviral agent, in particular as an anti-rna viral agent, and especially as an anti-rs viral agent. The invention provides a compound indicated by formula (1), wherein r1 each independently represent hydrogen, halogen, hydroxyl, amino, carboxyl, c1-c6 alkyl, c1-c6 alkoxyl, c1-c6 halogenoalkyl, c1-c6 alkoxycarbonyl, c1-c6 alkylamino, c2-c5 alkenyl, c3-c6 cycloalkyl, or optionally substituted aryl; r2 each independently represent hydrogen, c1-c6 alkyl, c1-c6 halogenoalkyl, c2-c5 alkenyl, c3-c6 cycloalkyl, optionally substituted aryl or heterocyclic group; and one or more r1 may be present in the same ring, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture of these.
National University Corporation Chiba University

Method for preparing a vaccine antigen, resulting vaccine antigen and uses

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (ii): wherein: x is a —(ch2)-co2y group and y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (ii) in carrier format, with a quantity of 0.1 to 1,000 μg in the total weight of the vaccine.
Inserm

Recombinant aav production in mammalian cells

The present invention includes methods and compositions for the production of high titer recombinant adeno-associated virus (raav) in a variety of mammalian cells. The disclosed raav are useful in gene therapy applications.
University Of Florida Research Foundation Incorporated

Cd47 targeted therapies for the treatment of infectious disease

Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of cd47 on a infected cell to sirpα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.. .
The Regents Of The University Of California

Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Novel synthetic biology-based adcc technologies are provided that enhance or enable adcc responses, for example, through a rationally-designed soluble universal adcc enhancer protein (suaep) where a high-affinity cd3-binding domain is fused to a high-affinity fc-binding domain. The suaep technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable..
1globe Biomedical Co., Ltd.

Infectious waste disposal

A system for treating infectious waste is provided that employs a medical waste handling and shredding sub-system that feeds partially processed waste to an oxidizer to eliminate potential airborne infectious waste prior to transforming the medical waste into useful co-products. Medical waste is transformed into value added products including hydrocarbon based gases, hydrocarbon-based liquids, carbonized material, and recovered precious metals and rare earth materials in a system having as its transformative element an anerobic, negative pressure, or carbonization system.
Aemerge Llc

Vaccine against infectious bronchitis virus

Embodiments of the present invention relate to an infectious bronchitis virus (ibv) and an immunogenic composition comprising an ibv, respectively, wherein the orf 3a and/or the orf 3b and/or the orf 5a and/or the orf 5b is inactivated. Furthermore, aspects of the present invention relate to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention.
Boehringer Ingelheim Vetmedica Gmbh

Peptidomimetic macrocycles and uses thereof

Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disorders, for example, for treatment of infectious diseases.. .
Aileron Therapeutics, Inc.

Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis

The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-pd-l1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.. .
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Compositions and methods related to viral vaccines

Provided herein are methods and compositions relating to infectious bursal disease virus (ibdv), and vaccines for treatment and prevention thereof.. .
Ohio State Innovation Foundation

Subunit immersion vaccines for fish

The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is f. Psychrophilum and/or infectious pancreatic necrosis virus (ipnv)..
Fvg Limited

Quaternary disinfectant composition with anionic scale inhibiting agent

The present invention relates to quaternary ammonium disinfecting cleaner compositions comprising a quaternary ammonium compound, an antimicrobial amine, and an anionic scale inhibitor. Beneficially, the compositions provide sanitizing efficacy without diminished performance and without scale formation when diluted with hard water.
Ecolab Usa Inc.

Devices, systems and methods to detect viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives

Various devices, systems and methods for detecting infectious agents or determining a susceptibility of an infectious agent to an anti-infective are described herein. One example method comprises introducing a fluid sample to a surface; exposing the surface to a solution; sampling the solution after exposing the solution to the surface; and detecting a change in an electrical characteristic of a sensing device exposed to the solution sampled corresponding to a presence of the infectious agent in the fluid sample..
Avails Medical, Inc.

Bandages for supplying ozone therapy

The present disclosure relates to a bandage wherein the bandage comprise of a first layer of protective covering, wherein the first layer is removable; a second layer of covering, wherein the second layer of covering is made of a cloth material; a third layer of covering, wherein the third layer is the top most layer of the bandage and together with the second layer forms a support pad; an injection, wherein the injection is present on the second layer of covering; a cylinder, wherein the cylinder is present in the support pad, wherein the bandage is used for delivering a medication to a localized area on a patient's body. The bandage is further used for delivering localized, painless ozone gas treatment to a patient suffering from infectious disease.
Umm-al-qura University

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur

Methods for making novel antigen binding domains

The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel cars that utilize the novel antigen binding domains as an extracellular element.
Chimera Bioengineering, Inc.

Methods and compositions for the activation of gamma-delta t-cells

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
American Gene Technologies International Inc.

Nitroimidazole compound, preparation method therefor and use thereof in drug manufacturing

A nitroimidazole compound represented by general formula (i) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a preparation method therefore, and use thereof in manufacturing drugs for the treating infectious diseases caused by mycobacterium tuberculosis. Specific groups in general formula (i) are as defined in the specification..
Shanghai Sun-sail Pharmaceutical Science & Technology Co., Ltd.

Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, non-alcholic fatty liver disease (nafld), non-alcholic steathohepatitis (nash), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.. .

Microfluidic processing of leukocytes for molecular diagnostic testing

Described herein are microfluidic devices and methods that can greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas..

Dosage and administration of non-fucosylated anti-cd40 antibodies

This invention relates methods of using a non-fucosylated anti-cd40 antibody for treatment of cancer and chronic infectious diseases.. .
Seattle Genetics, Inc.

Convergent and enantioselective total synthesis of communesin analogs

Or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein r1-r8 and m, n, r, s, t, and u are as defined herein, is provided. Methods of making such compounds are also disclosed as are methods for the treatment of cancer, various infectious diseases, and abnormal cardiovascular function..

Method for making ice cream

A method for making ice cream including the following steps, performed in the following order: heating the side walls of the processing container to a preset preheating temperature; placing a basic ice cream mixture in the processing chamber after the step of heating the side walls of the processing container to a preset preheating temperature; deactivating any infectious agents which may be present in the basic mixture by activating the thermal treatment system in heating mode for a predetermined time in order to pasteurize the basic mixture inside the processing chamber; keeping the basic mixture, previously subjected to the thermal treatment inside the processing chamber, for a predetermined hold time.. .
Ali S.p.a. - Carpigiani Group

Recombinant viral vectors

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative

Compositions and methods for the treatment of mucositis

The invention relates to the compounds of formula i, formula ii, formula iii, formula iv, formula v, formula vi, formula vii and formula viii, or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, formula ii, formula iii, formula iv, formula v, formula vi, formula vii and formula viii, and methods for the treatment of mucositis may be formulated for oral, mouth wash, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection.
Cellix Bio Private Limited

Dosage regimen for pegylated interferon

A pegylated type i interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 μg dose of the pegylated type i interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.. .
Pharmaessentia Corporation

Method of preparing mirabilitum praeparatum by pure strain fermentation and its applications

The present invention involves a method of preparing mirabilitum praeparatum by pure strain fermentation and its application in treating infectious and inflammatory diseases, as well as health products and cosmetics. The method involves blending the ripe fruit (watermelon) of citrullus lanatus (thumb.) matsumu.et nakai with mirabilite (na2so4.10h2o) according to a certain ratio as culture media and the pure strain penicillium rubens as zymocyte, and then fermenting under a certain temperature.

Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds

Compositions and compounds having nucleoside phosphoramidites, and methods of making the same are provided. The compounds can also have one or more amino groups that each can be positively charged.
Zata Pharmaceuticals, Inc.



Infectious topics:
  • Infectious
  • Infectious Disease
  • Infectious Diseases
  • Autoimmune
  • Autoimmune Disease
  • Immune Disease
  • Modulation
  • Nucleotide
  • Killer Cells
  • Natural Killer Cell
  • Stem Cells
  • Amplification
  • Dna Sequence
  • Single Nucleotide Polymorphism
  • Nucleic Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Infectious for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Infectious with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3848

    file did exist - file did put12862

    3 - 1 - 252